Clinical trialsCompany release

ArriVent's firmonertinib misses primary endpoint in Phase 3 FURVENT lung cancer trial

🇺🇸 ArriVent BioPharma, Inc. (AVBP) · Mon 09 Nov 2026

ArriVent BioPharma says firmonertinib did not meet progression-free survival goals in NSCLC, while reporting a cash position of $393.2 million that it expects to last to mid-2028.

ArriVent BioPharma reported on 9 November 2026 that its Phase 3 FURVENT trial of firmonertinib in non-small cell lung cancer (NSCLC) did not meet its primary endpoint of progression-free survival (PFS). The company announced the result alongside its third-quarter 2026 financial results.

According to the company, median PFS was 11.0 months in one arm against 9.5 months in the comparator, a hazard ratio of 0.75. The summary available does not specify which arm achieved which figure, nor does it give further detail on the statistical analysis, so those points remain unclear.

ArriVent said it is reviewing the FURVENT data and plans to provide an update in the first quarter of 2027. No decisions on the programme's regulatory path have been announced.

Elsewhere in its pipeline, the company said enrolment continues in the Phase 3 ALPACCA study in NSCLC with EGFR PACC mutations. It also reported that the first patient has been dosed in a Phase 1a/1b study of ARR-002, an antibody-drug conjugate (ADC).

ArriVent reported cash of $393.2 million, which it expects to fund operations to mid-2028.

What it means for your team

  • Regulatory teams tracking firmonertinib should expect no filing decision until ArriVent presents its full FURVENT analysis, which the company has scheduled for Q1 2027.
  • Market-access and competitive-intelligence teams in EGFR-mutant NSCLC should watch for subgroup and safety data, as only top-line PFS figures are currently available.
  • The ALPACCA study in EGFR PACC-mutant NSCLC and the ARR-002 ADC study remain active, so the company's pipeline activity continues despite the FURVENT result.

Company's press release (SEC filing): ArriVent BioPharma, Inc. ↗

Article written by VigiEye from the official source (ArriVent BioPharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →